Key results of the unaudited financials for the half year ending
|WDAS||For the six months ended|
WDAS is preparing for the Q2’14 dividend of
Full details of the Company's filings are accessible at http://www.otcmarkets.com/stock/WDAS/filings.
Our strong financial position allows us to continue our share buy back program and to invest in our research and product development activities, which underpins and drives our licensing activity and growth.
We are well placed to deliver on our technologies in development and anticipate sustained growth from our existing, proven revenue generating products and services and from our new, unique emerging technologies.”
This press release contains forward-looking statements. Words such as “expects”, “intends'', “believes'' and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.